Cellectis S.A. (EPA:ALCLS)
3.105
+0.095 (3.16%)
Apr 2, 2026, 5:35 PM CET
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
€298,632
Profits / Employee
€253,608
Market Cap
225.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 229 | 7 | 3.15% | 224 | 5 |
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Genfit | 188 |
| Innate Pharma | 174 |
| Transgene | 147 |
| MedinCell | 145 |
| Adocia | 77 |
| MaaT Pharma | 65 |
| OSE Immunotherapeutics | 64 |
Cellectis News
- 15 days ago - Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 22 days ago - Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - GlobeNewsWire
- 4 weeks ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 3 months ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 3 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire
- 3 months ago - Cellectis Announces Arbitral Decision in Dispute with Servier - GlobeNewsWire
- 4 months ago - ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL - GlobeNewsWire
- 4 months ago - Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells - GlobeNewsWire